Uveal melanoma

Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America

Retrieved on: 
星期三, 十一月 9, 2022
Growth, Cytokine release syndrome, Infection, Melanoma, Chills, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PIM, Rash, Bispecific monoclonal antibody, Vomiting, Nasdaq, Autoimmune disease, Immunocore, Risk, Hypotension, EMA, Uveal melanoma, European Medicines Agency, Vital signs, Partnership, Fatigue, CRS, Creatinine, Fetus, Eye, ALT, FDA, ImmTAC, Anti-CD3 monoclonal antibody, Headache, Melanocyte, LATAM, AST, Edema, Breakthrough therapy, CEO, Food, Birth, Nausea, Patient, Abdominal pain, TGA, Health Canada, Cancer, Lymphocyte, Pascal (microarchitecture), TCR, Hypoxia, Xeroderma, Itch, Glucose, Pharmaceutical industry, Medical device, Medical imaging, Fever, Medison

PETACH TIKVAH, Israel, Nov. 9, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced the addition of South and Central America and the Caribbean markets ("Latin America") to its multi-territorial agreement with Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease.

Key Points: 
  • "The expansion of our partnership with Immunocore into LATAM is a significant milestone in building our unified commercial platform in all international markets," says Meir Jakobsohn, Founder and CEO of Medison.
  • In this case, offering patients in Latin America hope in the form of a treatment for this rare and aggressive form of melanoma that affects the eye."
  • With this latest growth, Medison increases its commercial presence across Israel, Central and Eastern Europe, Canada, Asia-Pacific, South and Central America and the Caribbean countries.
  • Medison has a track record of multi-territorial partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach.

Castle Biosciences to Present at Upcoming Investor Conferences

Retrieved on: 
星期二, 十一月 1, 2022
Mental Health, Research, Infectious Diseases, Biotechnology, Other Health, Health, General Health, Science, Oncology, CG, Uveal melanoma, Atopic dermatitis, Credit, Health, Diagnosis, Conference, Nasdaq, Castle, Skin, View, Company, Patient, Medtech, Digital health, Credit Suisse, Pharmaceutical industry, Medical device, Facebook

Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum on Nov. 17, 2022, at 11:30 a.m. Eastern time.

Key Points: 
  • Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum on Nov. 17, 2022, at 11:30 a.m. Eastern time.
  • Live audio webcasts of the Companys presentations will be available on Castle Biosciences website at https://ir.castlebiosciences.com/events-presentations/default.aspx .
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005141/en/

Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma

Retrieved on: 
星期一, 十月 31, 2022
Oncology, Health, Genetics, Other Health, Research, Science, Biotechnology, Health, Atopic dermatitis, NCCN, Cancer Investigation, Personal Data Privacy and Security Act of 2009, National Comprehensive Cancer Network, Physician, Securities Act of 1933, Birbal Trilogy Case 1: Finding Vajramuni, Publication, Patient, Lymph node, CSCC, SEC, Uveal melanoma, Risk, Indiana University School of Medicine, SCC, Company, Securities Exchange Act of 1934, Journal of the National Comprehensive Cancer Network, Nasdaq, Population, Prognosis, Skin, Department, Pharmaceutical industry, Risk management, Medical device, Medical imaging, Facebook

The paper, titled Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-GEP Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients, evaluated metrics from one year of clinical DecisionDx-SCC orders and the tests impact on real-world risk assessments and treatment decisions.

Key Points: 
  • The paper, titled Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-GEP Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients, evaluated metrics from one year of clinical DecisionDx-SCC orders and the tests impact on real-world risk assessments and treatment decisions.
  • The clinicians who responded (n=34) were generally well-aligned regarding the different baseline risk levels (pre-test) inherent in each of these real-world patient cases.
  • DecisionDx-SCC is a 40-gene expression profile test that uses an individual patients tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.
  • Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make.

Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program

Retrieved on: 
星期四, 十月 27, 2022
Research, Clinical Trials, Biotechnology, Other Health, Managed Care, Health, Other Science, Science, Oncology, Collection, Securities Act of 1933, Instagram, Securities Exchange Act of 1934, MSS, IIB, Company, Atopic dermatitis, SLN, UM, III, American Joint Committee on Cancer, IIC, Health, Sentinel lymph node, Recurrence, International Congress on Tuberculosis, SMR, National Cancer Institute, FDA, Patient, AJCC, Melanoma Research, SEC, GEP, DecisionDx-UM, Uveal melanoma, National, CM, Survival, Melanoma, Twitter, Death, Society, NCI, Disease, Program, Nasdaq, Registry, National Comprehensive Cancer Network, Surveillance, SEER, Cohort study, Drug Quality and Security Act, Journal of the National Comprehensive Cancer Network, Disease management, NCCN, LinkedIn, Risk, Metastasis, List of life sciences, Pharmaceutical industry, Vaccine, Medical device, Medical imaging, Facebook, Epidemiology

The studies are part of the Companys ongoing collaboration with the National Cancer Institute (NCI) to link DecisionDx-Melanoma and DecisionDx-UM clinical testing data with data from the Surveillance, Epidemiology and End Results (SEER) Programs registries on CM and UM cases, respectively.

Key Points: 
  • The studies are part of the Companys ongoing collaboration with the National Cancer Institute (NCI) to link DecisionDx-Melanoma and DecisionDx-UM clinical testing data with data from the Surveillance, Epidemiology and End Results (SEER) Programs registries on CM and UM cases, respectively.
  • The data were shared in poster presentations at the 19th International Congress of the Society for Melanoma Research (SMR) in Edinburgh, United Kingdom.
  • In the study, DecisionDx-Melanoma was a statistically significant and independent predictor of melanoma-specific survival (MSS), consistent with previously published retrospective and prospective studies.
  • Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make.

Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors

Retrieved on: 
星期一, 十月 24, 2022
Other Health, Health, Science, Research, Oncology, Physician, LinkedIn, Lung, SLN, Uncertainty, Personal Data Privacy and Security Act of 2009, Dermatology, Risk, SEC, Conference, SEER, Patient, Surveillance, Publication, Twitter, List of life sciences, Instagram, Securities Act of 1933, Metastasis, Nasdaq, Sentinel lymph node, Malignancy, Company, Prostate, Medicare, Health, Atopic dermatitis, Skin, Breast, Securities Exchange Act of 1934, Castle, Recurrence, Survival, Melanoma, CSCC, Â, Disease management, Uveal melanoma, 2022 Formula One World Championship, Poster, Medical device, Medical imaging, Facebook, Epidemiology

In this analysis of Medicare-eligible patients with high-risk cSCC (n=59), clinicians indicated that the DecisionDx-SCC test result was the most influential factor impacting their management plans for 42% of the patients.

Key Points: 
  • In this analysis of Medicare-eligible patients with high-risk cSCC (n=59), clinicians indicated that the DecisionDx-SCC test result was the most influential factor impacting their management plans for 42% of the patients.
  • DecisionDx-SCC is a 40-gene expression profile test that uses an individual patients tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.
  • The test result, in which patients are stratified into a Class 1 (low), 2A (moderate) or 2B (high) risk category, predicts individual metastatic risk to inform risk-appropriate management.
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.

Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2

Retrieved on: 
星期三, 十月 19, 2022
Medical Devices, Other Health, Health, Pharmaceutical, Medical Supplies, LinkedIn, Question and Answer, Webcast, Investor relations, Patient, List of life sciences, Twitter, Instagram, Nasdaq, Company, Health, Atopic dermatitis, Skin, Uveal melanoma, View, Medical device, Facebook

Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Key Points: 
  • Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
  • A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/748805907 or via the webcast link on the Investor Relations page of the Companys website , https://ir.castlebiosciences.com/overview/default.aspx .
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005130/en/

Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting

Retrieved on: 
星期二, 十月 11, 2022
Oncology, Health, Medical Devices, Genetics, Research, Science, Biotechnology, LinkedIn, Uncertainty, Securities Act of 1933, Dermatology, Risk, SEC, Diagnosis, Patient, List of life sciences, Twitter, Instagram, Annual general meeting, Nasdaq, Malignancy, Company, Health, Atopic dermatitis, Skin, Dermatoscopy, Securities Exchange Act of 1934, Castle, College, GEP, Uveal melanoma, Medical imaging, Facebook

In the case study presented during the College of American Pathologists 2022 (CAP22) Annual Meeting, DiffDx-Melanoma supported the need to perform a local excision on a difficult-to-diagnose melanocytic lesion after clinicopathological correlation was not achieved by dermoscopy, reflectance confocal microscopy and/or histopathological assessment alone.

Key Points: 
  • In the case study presented during the College of American Pathologists 2022 (CAP22) Annual Meeting, DiffDx-Melanoma supported the need to perform a local excision on a difficult-to-diagnose melanocytic lesion after clinicopathological correlation was not achieved by dermoscopy, reflectance confocal microscopy and/or histopathological assessment alone.
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
  • The word can and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

Retrieved on: 
星期一, 十月 10, 2022
TCR, LinkedIn, DL, Engineering, CRS, SEC, Webcast, Head, Investor, Neoplasm, DLT, RECIST, Patient, Cytokine release syndrome, Twitter, SD, Evelyn, Cancer Prevention and Research Institute of Texas, Cancer, Research institute, CT, Trial of the century, Ovarian cancer, MD, PRAME, Â, Adoptive cell transfer, ORR, Nature, CEST, Safety, EDT, Cancer prevention, Melanoma, Clinical trial, Forward-looking statement, Corr, Terminology, Uveal melanoma, Half-life, University of Texas Health Science Center at Houston, Medical imaging, Pharmaceutical industry, Vaccine

In addition to this first data from IMA203 monotherapy today, we are awaiting data from two additional dose expansion cohorts: IMA203 together with an immune checkpoint inhibitor and our 2nd generation product candidate IMA203CD8.

Key Points: 
  • In addition to this first data from IMA203 monotherapy today, we are awaiting data from two additional dose expansion cohorts: IMA203 together with an immune checkpoint inhibitor and our 2nd generation product candidate IMA203CD8.
  • Safety data for IMA203 monotherapy across Phase 1a and Phase 1b: Treatment with IMA203 continues to show manageable tolerability profile.
  • Phase 1b Cohort A - Clinical activity: IMA203 monotherapy demonstrates high confirmed objective response rate of 80% with early signs of prolonged durability.
  • Immatics will host a conference call today, October 10, 2022, at 8:30 am EDT / 2:30pm CEST to discuss these clinical data.

Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

Retrieved on: 
星期一, 十月 10, 2022
Research, Surgery, Genetics, Biotechnology, Other Health, Health, Other Science, Science, Oncology, Aurora, LinkedIn, SLN, Uncertainty, Internal Security Act (Singapore), Dermatology, Risk, SEC, National Comprehensive Cancer Network, ACMS, Society, American College of Mohs Surgery, Patient, NCCN, SEER, Surveillance, Twitter, Publication, Instagram, List of life sciences, Annual general meeting, Securities Act of 1933, Metastasis, Nasdaq, Sentinel lymph node, Malignancy, Company, Health, Atopic dermatitis, Skin, SCC, Castle, Recurrence, Survival, Melanoma, GEP, CSCC, P.C, Disease management, ASDS, American College, Uveal melanoma, Skin cancer, Securities Exchange Act of 1934, Pharmaceutical industry, Medical imaging, Medical device, Medicine, Silviculture, Facebook, Epidemiology

97% of respondents were at least somewhat familiar with or had used the DecisionDx-SCC test.

Key Points: 
  • 97% of respondents were at least somewhat familiar with or had used the DecisionDx-SCC test.
  • DecisionDx-Melanomas clinical value is supported by more than 35 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the tests results.
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make.

New VISION Registry Report Summarizes Key Ocular Melanoma Patient-Reported Data to Advance Clinical Research and Treatments

Retrieved on: 
星期一, 十月 3, 2022
Massachusetts General Hospital, CURE, Facebook, Melanoma, Health status of White Americans, Hospital, Australian Melanoma Research Foundation, Physician, Research, OM, Industry, Disease, Health, Twitter, Investor, Uveal melanoma, Patient, Education, Goal, Caregiver, Biopsy, Eye, Quality of life, Communication, MRF, Leadership, ISOO, Acral lentiginous melanoma, HRQOL, Diagnosis, MD Anderson Cancer Center, Development and Educational Communication Unit, FACS, Organization, Awareness, Medicine, Telescopic sight, MD, Ophthalmology

WASHINGTON, Oct. 3, 2022 /PRNewswire-PRWeb/ -- Today, the Melanoma Research Foundation's (MRF) CURE OM initiative, dedicated to increasing awareness, education, support and research funding for ocular melanoma (OM) released its first-ever data report highlighting its Virtual Information System to Improve Outcomes and Networks (VISION) Registry's inaugural year. Launched in May 2021, VISION tracks patients from the time of diagnosis through their full experience with ocular melanoma. Patients from around the world can share their experiences with this rare disease to help advance patient care, quality of life and ultimately find a cure for OM. VISION collects patient-reported outcomes such as symptoms, health-related quality of life (HRQOL), perceived health status, experience with the health system and preferences to inform stakeholders on the patient experience. Understanding this holistic experience is pivotal to identify potential causes, improve quality of patient care and enhance clinical research resulting in better therapeutic interventions.

Key Points: 
  • Launched in May 2021, VISION tracks patients from the time of diagnosis through their full experience with ocular melanoma.
  • The VISION Registry Data Report provides key takeaways and accomplishments from the registry's first year and establishes a strong and impressive framework for future patient-centered resources, collaboration and research.
  • The report offers insight into areas such as socio-demographics, clinical care, patient experience, patient preferences and quality of life.
  • To view additional patient reported data and read OM community testimonials, you can access the 2022 VISION Registry Data Report here: melanoma.org/VisionDataReport .